...
首页> 外文期刊>Physiological Reports >Regulation of cell proliferation by the guanosine–adenosine mechanism: role of adenosine receptors
【24h】

Regulation of cell proliferation by the guanosine–adenosine mechanism: role of adenosine receptors

机译:鸟苷-腺苷机制对细胞增殖的调节:腺苷受体的作用

获取原文
           

摘要

AbstractA recent study (American Journal of Physiology – Cell Physiology 304:C406–C421, 2013) suggests that extracellular guanosine increases extracellular adenosine by modifying the disposition of extracellular adenosine (“guanosine–adenosine mechanism”) and that the guanosine–adenosine mechanism is not mediated by classical adenosine transport systems (SLC28 and SLC29 families) nor by classical adenosine-metabolizing enzymes. The present investigation had two aims (1) to test the hypothesis that the “guanosine–adenosine mechanism” affects cell proliferation; and (2) to determine whether the transporters SLC19A1, SLC19A2, SLC19A3, or SLC22A2 (known to carrier guanosine analogs) might be responsible for the guanosine–adenosine mechanism. In the absence of added adenosine, guanosine had little effect on the proliferation of coronary artery vascular smooth muscle cells (vascular conduit cells) or preglomerular vascular smooth muscle cells (vascular resistance cells). However, in the presence of added adenosine (3 or 10 μmol/L), guanosine (10–100 μmol/L) decreased proliferation of both cell types, thus resulting in a highly significant (P  0.000001) interaction between guanosine and adenosine on cell proliferation. The guanosine–adenosine interaction on cell proliferation was abolished by 1,3-dipropyl-8-(p-sulfophenyl)xanthine (adenosine receptor antagonist). Guanosine (30 μmol/L) increased extracellular levels of adenosine when adenosine (3 μmol/L) was added to the medium. This effect was not reproduced by high concentrations of methotrexate (100 μmol/L), thiamine (1000 μmol/L), chloroquine (1000 μmol/L), or acyclovir (10,000 μmol/L), archetypal substrates for SLC19A1, SLC19A2, SLC19A3, and SLC22A2, respectively; and guanosine still increased adenosine levels in the presence of these compounds. In conclusion, the guanosine–adenosine mechanism affects cell proliferation and is not mediated by SLC19A1, SLC19A2, SLC19A3, or SLC22A2.
机译:摘要最近的一项研究(美国生理学杂志–细胞生理学304:C406–C421,2013)表明,胞外鸟苷通过修饰胞外腺苷的分布来增加胞外腺苷(“鸟苷-腺苷机制”),而鸟苷-腺苷机制并非如此由经典的腺苷转运系统(SLC28和SLC29家族)介导,也不受经典的腺苷代谢酶介导。目前的研究有两个目的(1)检验“鸟苷-腺苷机制”影响细胞增殖的假说; (2)确定转运蛋白SLC19A1,SLC19A2,SLC19A3或SLC22A2(已知携带鸟苷类似物)可能是鸟苷-腺苷机制的原因。在不添加腺苷的情况下,鸟苷对冠状动脉血管平滑肌细胞(血管导管细胞)或肾小球前血管平滑肌细胞(血管阻力细胞)的增殖影响很小。但是,在添加腺苷(3或10μmol/ L)的情况下,鸟苷(10-100μmol/ L)降低了两种细胞的增殖,因此导致鸟苷和腺苷之间的相互作用显着(P <0.000001)细胞增殖。 1,3-二丙基-8-(对-磺苯基)黄嘌呤(腺苷受体拮抗剂)消除了鸟嘌呤-腺苷对细胞增殖的相互作用。当将腺苷(3μmol/ L)加入培养基中时,鸟苷(30μmol/ L)增加了腺苷的细胞外水平。高浓度的甲氨蝶呤(100μmol/ L),硫胺素(1000μmol/ L),氯喹(1000μmol/ L)或阿昔洛韦(10,000μmol/ L),SLC19A1,SLC19A2,SLC19A3的原型底物均不能重现这种作用,和SLC22A2分别;在存在这些化合物的情况下,鸟苷和鸟苷仍会增加腺苷水平。总之,鸟苷-腺苷机制影响细胞增殖,并且不受SLC19A1,SLC19A2,SLC19A3或SLC22A2的介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号